Cereno Scientific extends preclinical development agreement with University of Michigan to transition CS014 into clinical phase
Cereno Scientific today announced that the collaboration agreement for CS014 with the University of Michigan will be extended to include a full preclinical development program. The objective of the signed development agreement is to successfully bring CS014 into a clinical Phase I program. The IND-enabling work will be conducted at the University of Michigan, a top-ranked public research university in the US with an extensive track record of successful collaborations with industry. CS014 is in development within cardiovascular diseases.“We started working with Dr. Michael Holinstat and his